ClinCalc Pro
Menu
Nitrosourea alkylating agent

Lomustine (Specialist drug)

Brand names: CCNU

Adult dose

Dose: Specialist initiation only — refer to BNF/SmPC; typically 100–130 mg/m² every 6 weeks
Route: PO
Frequency: q6w

Clinical pearls

  • High-grade glioma, Hodgkin lymphoma
  • Crosses blood-brain barrier

Contraindications

  • Severe myelosuppression
  • Severe renal/hepatic impairment
  • Pregnancy/breastfeeding

Side effects

  • Severe delayed myelosuppression (nadir 4–6 weeks)
  • Pulmonary fibrosis (cumulative)
  • Nephrotoxicity
  • Hepatotoxicity
  • Secondary malignancy
  • Severe nausea/vomiting

Interactions

  • Live vaccines
  • Other myelosuppressants

Monitoring

  • FBC weekly post-dose
  • LFTs
  • U&E
  • Pulmonary function

Reference: BNF; SmPC; https://bnf.nice.org.uk/drugs/lomustine-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.

Related

Curated clinical cross-links plus same-class fallbacks.